For the first time, an Israeli man who had previously recovered from a coronovirus was found to be corroborated with the so-called South African strain on Sunday, Hebrew media reported.
The diagnosis continued amid uncertainty over the effectiveness of the Pfizer / BioNTech vaccine, which Israel is using for its mass vaccination program against new strains of the virus.
Zeev Yaf, 57, from the central region of the country, has recently returned from Turkey. Speaking to Channel 12 News, he said he had “all the symptoms” during his first infection in August, the second time he felt well.
Get the daily edition of the Times of Israel by email and never miss our top stories by signing up for free
Yaf returned to Israel on 16 January. By 23 January, he had a runny nose and decided to undergo a virus test, as he was participating in follow-up research at Asaf Harofeh Medical Center. Testing showed that he was athletic and further testing revealed that he had caught the South African mutation.
Shai Efrati, head of research and development at the medical center, told the station that the case of Yafé was unique because doctors had a complete medical record of his encounters with the virus.
“This is the first time that we have a complete record of infection, recovery, reinforcement, and that antibodies had protected them from mutations,” Eferty said.
“What we learn is that when there are antibodies, they protect against disease,” he said.
Ephrati cautioned that it would be too early to conclude that anyone who has the disease is protected against other mutations as well, adding that similar cases would be needed before such a conclusion could be made.
But, he said, Yuff’s case is “very encouraging.”
Yaff said that apart from not feeling unwell, family members and others were in close contact with him during the period of his second infection, yet no one caught the virus.
His case is the second time the South African version has been brought from Israel to Turkey, according to the Ynet website.
Health officials are concerned that South African mutations similar to British and California strains, which are thought to be more contagious, could cause another wave of the virus in people who have recovered from previous infections and as part of an immunological drive Not being vaccinated.
According to the report, all previous South African patients, previously discovered in South Africa, returned to the country from South Africa, Ethiopia or Dubai in December.
On Saturday, the head of public health services at the Ministry of Health, Drs. Sharon Aloyer-Preiss told the Cannes public broadcaster that there were initial indications that coronovirus vaccines may prove less effective in shielding against South Korean variants.
“We do not yet have any evidence that any variant is completely resistant to the vaccine, but there is some preliminary evidence to say that perhaps the vaccine’s effectiveness is somewhat lower than in the South African version,” Alro- Preiss said.
He said the trial was on to clarify the case.
Pfizer and BioNTech, whose vaccines are being used in Israel’s world-leading vaccine drive, said on Thursday that initial tests showed their vaccination would be protective against variants in South Africa and Britain.
Their study found that antibodies were able to neutralize all sets of mutations tested. It was noted that the effect was “slightly lower” against three mutations in variants found in South Africa, including E484K. But the firms said that it was “unlikely to significantly decrease the effectiveness of the vaccine.”
The Ministry of Health confirmed last week that three more cases of South African coronovirus variants have been found in Israel, bringing the total number of stress-related infections to 30. A random sample was discovered in three cases, raising concerns of undesirable community. spread.
Meanwhile, the British version is spreading wildly in Israel, with health officials blaming the high coronavirus caseloid released after weeks of lockdown on UK mutations. Despite Israel’s strict restrictions and vaccination campaigns, daily infections continue into the thousands.
More than 3 million Israelis – about a third of their population – have received their first dose of the vaccine, and 1.7 million have received both shots. The shots are being administered according to a plan that began with medical personnel under 60 years of age and in at-risk groups, with age limits more civilians completing the two-shot vaccination cycle.
In an effort to keep the virus variants out of the country, Israel has closed its main international airport, including its own citizens. The order is scheduled to end on Sunday, but will likely be extended.
It is expected that the government will extend the nationwide lockout in another week to reduce the infection rate on Sunday.
According to data released by the Ministry of Health on Sunday, 641,373 people have been detected with the virus since the outbreak of the virus early last year. The death toll was 4,768.
Agencies contributed to this report.